- call +1-201-465-4211
- email sales@mrinsights.biz
Uterine fibroids (myoma) are benign (non-cancerous) lumps that grow in the muscular wall of the uterus. They vary in sizes, from minute (a quarter of an inch) to the size of more than16 centimeters. The incidence of uterine fibroid is about 20%–40% in women during their reproductive ages. Occasionally, these fibroids swell up and make the uterus to grow like full visible pregnancy. Mostly, there are more than one fibroid in the uterus. However, fibroids do not always cause any symptoms, their location, and size results to difficulties for few women, including pain, discomfort and heavy bleeding. Uterine fibroid can be of different types such as intramural fibroids, subserosal fibroids, pedunculated fibroids and submucosal fibroids. There can be many reasons for uterine fibroid formation but genetic problems hormonal imbalance and other factors are predominant. The cardinal symptoms of uterine fibroids are heavy menstrual bleeding, abdominal pain, excessive uterine bleeding, increased urinary frequency, anaemia and infertility. Apart from physical morbidity, uterine fibroid ailment is a frequent cause of significant damage of quality of life and a major reason for hysterectomy. Therapy has traditionally based on two extremes: medicinal management, comprising progestins, oral contraceptives and GnRH agonists and surgical management, including myomectomy, hysterectomy, and ablation for most serious cases.
Scope of the Report:
This report studies the Uterine Fibroids market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Uterine Fibroids market by product type and applications/end industries.
Patients suffering from uterine fibroid problem represent an undeserved and huge market due to the absence of satisfactory medical treatments. Uterine fibroids affects nearly 40% of women in the age group of 30 and 55, including 20 million women in North America and 24 million women in Europe with over 7 million patients worldwide presently undergo various symptom management treatments.
The global Uterine Fibroids market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Uterine Fibroids.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Boston Scientific
Cooper Surgical
C.R. Bard
F. Hoffmann-La Roche
GE Healthcare
Karl Storz Endoscopy
Richard Wolf Medical Instruments
Siemens Medical Solutions
AbbVie
AstraZeneca
Bayer
Eli Lilly
GlaxoSmithKline Pharmaceuticals
Pfizer
Johnson & Johnson
Novartis
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Non-Hormonal Treatment
Hormonal Treatment
Market Segment by Applications, can be divided into
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Others
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Uterine Fibroids Market Overview
1.1 Product Overview and Scope of Uterine Fibroids
1.2 Classification of Uterine Fibroids by Types
1.2.1 Global Uterine Fibroids Revenue Comparison by Types (2017-2023)
1.2.2 Global Uterine Fibroids Revenue Market Share by Types in 2017
1.2.3 Non-Hormonal Treatment
1.2.4 Hormonal Treatment
1.3 Global Uterine Fibroids Market by Application
1.3.1 Global Uterine Fibroids Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Diagnostic Centers
1.3.5 Others
1.4 Global Uterine Fibroids Market by Regions
1.4.1 Global Uterine Fibroids Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Uterine Fibroids Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Uterine Fibroids Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Uterine Fibroids Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Uterine Fibroids Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Uterine Fibroids Status and Prospect (2013-2023)
1.5 Global Market Size of Uterine Fibroids (2013-2023)
2 Manufacturers Profiles
2.1 Boston Scientific
2.1.1 Business Overview
2.1.2 Uterine Fibroids Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Boston Scientific Uterine Fibroids Revenue, Gross Margin and Market Share (2016-2017)
2.2 Cooper Surgical
2.2.1 Business Overview
2.2.2 Uterine Fibroids Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Cooper Surgical Uterine Fibroids Revenue, Gross Margin and Market Share (2016-2017)
2.3 C.R. Bard
2.3.1 Business Overview
2.3.2 Uterine Fibroids Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 C.R. Bard Uterine Fibroids Revenue, Gross Margin and Market Share (2016-2017)
2.4 F. Hoffmann-La Roche
2.4.1 Business Overview
2.4.2 Uterine Fibroids Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 F. Hoffmann-La Roche Uterine Fibroids Revenue, Gross Margin and Market Share (2016-2017)
2.5 GE Healthcare
2.5.1 Business Overview
2.5.2 Uterine Fibroids Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 GE Healthcare Uterine Fibroids Revenue, Gross Margin and Market Share (2016-2017)
2.6 Karl Storz Endoscopy
2.6.1 Business Overview
2.6.2 Uterine Fibroids Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Karl Storz Endoscopy Uterine Fibroids Revenue, Gross Margin and Market Share (2016-2017)
2.7 Richard Wolf Medical Instruments
2.7.1 Business Overview
2.7.2 Uterine Fibroids Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Richard Wolf Medical Instruments Uterine Fibroids Revenue, Gross Margin and Market Share (2016-2017)
2.8 Siemens Medical Solutions
2.8.1 Business Overview
2.8.2 Uterine Fibroids Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Siemens Medical Solutions Uterine Fibroids Revenue, Gross Margin and Market Share (2016-2017)
2.9 AbbVie
2.9.1 Business Overview
2.9.2 Uterine Fibroids Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 AbbVie Uterine Fibroids Revenue, Gross Margin and Market Share (2016-2017)
2.10 AstraZeneca
2.10.1 Business Overview
2.10.2 Uterine Fibroids Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 AstraZeneca Uterine Fibroids Revenue, Gross Margin and Market Share (2016-2017)
2.11 Bayer
2.11.1 Business Overview
2.11.2 Uterine Fibroids Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Bayer Uterine Fibroids Revenue, Gross Margin and Market Share (2016-2017)
2.12 Eli Lilly
2.12.1 Business Overview
2.12.2 Uterine Fibroids Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Eli Lilly Uterine Fibroids Revenue, Gross Margin and Market Share (2016-2017)
2.13 GlaxoSmithKline Pharmaceuticals
2.13.1 Business Overview
2.13.2 Uterine Fibroids Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 GlaxoSmithKline Pharmaceuticals Uterine Fibroids Revenue, Gross Margin and Market Share (2016-2017)
2.14 Pfizer
2.14.1 Business Overview
2.14.2 Uterine Fibroids Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Pfizer Uterine Fibroids Revenue, Gross Margin and Market Share (2016-2017)
2.15 Johnson & Johnson
2.15.1 Business Overview
2.15.2 Uterine Fibroids Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Johnson & Johnson Uterine Fibroids Revenue, Gross Margin and Market Share (2016-2017)
2.16 Novartis
2.16.1 Business Overview
2.16.2 Uterine Fibroids Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Novartis Uterine Fibroids Revenue, Gross Margin and Market Share (2016-2017)
3 Global Uterine Fibroids Market Competition, by Players
3.1 Global Uterine Fibroids Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Uterine Fibroids Players Market Share
3.2.2 Top 10 Uterine Fibroids Players Market Share
3.3 Market Competition Trend
4 Global Uterine Fibroids Market Size by Regions
4.1 Global Uterine Fibroids Revenue and Market Share by Regions
4.2 North America Uterine Fibroids Revenue and Growth Rate (2013-2018)
4.3 Europe Uterine Fibroids Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Uterine Fibroids Revenue and Growth Rate (2013-2018)
4.5 South America Uterine Fibroids Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Uterine Fibroids Revenue and Growth Rate (2013-2018)
5 North America Uterine Fibroids Revenue by Countries
5.1 North America Uterine Fibroids Revenue by Countries (2013-2018)
5.2 USA Uterine Fibroids Revenue and Growth Rate (2013-2018)
5.3 Canada Uterine Fibroids Revenue and Growth Rate (2013-2018)
5.4 Mexico Uterine Fibroids Revenue and Growth Rate (2013-2018)
6 Europe Uterine Fibroids Revenue by Countries
6.1 Europe Uterine Fibroids Revenue by Countries (2013-2018)
6.2 Germany Uterine Fibroids Revenue and Growth Rate (2013-2018)
6.3 UK Uterine Fibroids Revenue and Growth Rate (2013-2018)
6.4 France Uterine Fibroids Revenue and Growth Rate (2013-2018)
6.5 Russia Uterine Fibroids Revenue and Growth Rate (2013-2018)
6.6 Italy Uterine Fibroids Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Uterine Fibroids Revenue by Countries
7.1 Asia-Pacific Uterine Fibroids Revenue by Countries (2013-2018)
7.2 China Uterine Fibroids Revenue and Growth Rate (2013-2018)
7.3 Japan Uterine Fibroids Revenue and Growth Rate (2013-2018)
7.4 Korea Uterine Fibroids Revenue and Growth Rate (2013-2018)
7.5 India Uterine Fibroids Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Uterine Fibroids Revenue and Growth Rate (2013-2018)
8 South America Uterine Fibroids Revenue by Countries
8.1 South America Uterine Fibroids Revenue by Countries (2013-2018)
8.2 Brazil Uterine Fibroids Revenue and Growth Rate (2013-2018)
8.3 Argentina Uterine Fibroids Revenue and Growth Rate (2013-2018)
8.4 Colombia Uterine Fibroids Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Uterine Fibroids by Countries
9.1 Middle East and Africa Uterine Fibroids Revenue by Countries (2013-2018)
9.2 Saudi Arabia Uterine Fibroids Revenue and Growth Rate (2013-2018)
9.3 UAE Uterine Fibroids Revenue and Growth Rate (2013-2018)
9.4 Egypt Uterine Fibroids Revenue and Growth Rate (2013-2018)
9.5 Nigeria Uterine Fibroids Revenue and Growth Rate (2013-2018)
9.6 South Africa Uterine Fibroids Revenue and Growth Rate (2013-2018)
10 Global Uterine Fibroids Market Segment by Type
10.1 Global Uterine Fibroids Revenue and Market Share by Type (2013-2018)
10.2 Global Uterine Fibroids Market Forecast by Type (2018-2023)
10.3 Non-Hormonal Treatment Revenue Growth Rate (2013-2023)
10.4 Hormonal Treatment Revenue Growth Rate (2013-2023)
11 Global Uterine Fibroids Market Segment by Application
11.1 Global Uterine Fibroids Revenue Market Share by Application (2013-2018)
11.2 Uterine Fibroids Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Ambulatory Surgical Centers Revenue Growth (2013-2018)
11.5 Diagnostic Centers Revenue Growth (2013-2018)
11.6 Others Revenue Growth (2013-2018)
12 Global Uterine Fibroids Market Size Forecast (2018-2023)
12.1 Global Uterine Fibroids Market Size Forecast (2018-2023)
12.2 Global Uterine Fibroids Market Forecast by Regions (2018-2023)
12.3 North America Uterine Fibroids Revenue Market Forecast (2018-2023)
12.4 Europe Uterine Fibroids Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Uterine Fibroids Revenue Market Forecast (2018-2023)
12.6 South America Uterine Fibroids Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Uterine Fibroids Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Uterine Fibroids Picture
Table Product Specifications of Uterine Fibroids
Table Global Uterine Fibroids and Revenue (Million USD) Market Split by Product Type
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
